摘要
目的:观察雷米普利与阿托伐他汀单用或联用对糖尿病肾病的肾脏保护作用。方法:54例糖尿病肾病患者随机分为A、B、C组:A组口服雷米普利5mg·d-1;B组口服阿托伐他汀10mg·d-1;C组联合用雷米普利与阿托伐他汀,剂量同前。3组疗程均为18周。结果:3组的尿蛋白量和血脂均降低(P<0·01),C组尿蛋白降低幅度大于A组和B组(P<0·01,P<0·05),且C组的血脂改变程度优于A组和B组(P<0·01,P<0·05);3组血压、血肌酐、尿素氮均下降,差异无显著意义(P>0·05)。结论:雷米普利与阿托伐他汀治疗糖尿病肾病均可获得良好作用,但两药合用较两药单用肾保护作用更显著。
OBJECTIVE： To observe the renal protective effects of ramipril and atorvastatin used in combination or alone for diabetic nephropathy. METHODS： 54 patients were randomly assigned to receive ramipril 5 mg q.d （Group A）, atorvastatin 10 mg q.d （Group B） or ramipri 5mg qd ＋ atorvastatin 10mg q.d （Group C） for 18wk. RESULTS： After 18-week treatment, levels of both urine protein and blood lipid decreased in all the three groups （P〈0.01） . The increasing rate of urine protein in Group C was higher than in groups A and B （P〈0.01,P〈0.05） and the improvement in blood lipid was better in Group C than in groups A and B （P〈0.01, P〈0.05） . Blood pressure, Scr and BUN decreased in all groups, but with no significant difference among groups（P 〉0.05）. CONCLUSION： Either Ramipril or Atorvastatin alone had satisfactory effect on diabetic nephropathy, but a more remarkable protection effect on kidney was noted when they used in combination.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第11期850-851,共2页
China Pharmacy
